# A Study of Clevidipine Butyrate Injectable Emulsion in the Treatment of Hypertensive Emergency and Sub-emergency

Study · id `cardio:ct-nct05783557` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05783557](<https://clinicaltrials.gov/study/NCT05783557>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05783557

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 398 participants.

## Technical summary

Registry record NCT05783557. Randomized; triple masking; primary purpose treatment. Start 2023-05-01 (anticipated); primary completion 2024-12-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 398 participants (planned count; ClinicalTrials.gov record NCT05783557, source copy `cardio:ctgov-nct05783557-2023-03-24`, retrieved 2026-10-26)
- Planned start: 2023-05-01 (anticipated) (ClinicalTrials.gov record NCT05783557, source copy `cardio:ctgov-nct05783557-2023-03-24`, retrieved 2026-10-26)
- Primary completion: 2024-12-01 (anticipated) (ClinicalTrials.gov record NCT05783557, source copy `cardio:ctgov-nct05783557-2023-03-24`, retrieved 2026-10-26)
- Completion: 2025-06-01 (anticipated) (ClinicalTrials.gov record NCT05783557, source copy `cardio:ctgov-nct05783557-2023-03-24`, retrieved 2026-10-26)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05783557-2023-03-24`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Study of Clevidipine Butyrate Injectable Emulsion in the Treatment of Hypertensive Emergency and Sub-emergency
- Condition: Hypertensive Emergency
- Intervention (Drug): Clevidipine Butyrate Injectable Emulsion
- Intervention (Drug): Cleviprex®
- Lead sponsor: CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry lists this organization as the lead sponsor: CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. (`cardio:org-cspc-zhongnuo-pharmaceutical-shijiazhuang-co-ltd`)

## Provenance

Content hash: ec108508fe807643c0b607258466377757fdf9b4f6e3ff0ce0b679c536fbb198
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
